Venn Life Sciences Holdings (VENN)

 

VENN Share PerformanceMore

52 week high21.980 06/03/17
52 week low8.000 21/02/18
52 week change -10.950 (-56.15%)
4 week volume1,759,033 28/01/18
price8.550
price date1519384648
close8.750

Latest NewsMore

Venn revenue declines after project deferrals

Venn Life Sciences, a drug development partner, saw a decline in its revenue from 18.2m to 17.8m in 2017. The company sa...

Trading Statement

RNS Number: 9326E Venn Life Sciences Holdings PLC 15 February 2018 15 February 2018 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Trading and Strategy Update Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutic...

Change of Adviser

RNS Number: 8529C Venn Life Sciences Holdings PLC 25 January 2018 25 January 2018 Venn Life Sciences Holdings plc ("Venn" or the "Company" or the "Group") Appointment of Nominated Adviser and Broker Venn Life Sciences Holdings plc, the AIM drug development services organisation, announces the appointment of Cenkos Securities plc as its Nominated...

Venn Life Sciences buys out French partner

Venn Life Sciences Holdings has agreed to acquire the 11% of Venn Life Sciences France that it doesn't already own from C...

Acquisition of Minority Interest

RNS Number: 5893C Venn Life Sciences Holdings PLC 23 January 2018 23 January 2018 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Acquisition of Minority Interest Venn Life Sciences Holdings PLC ("VLS"), today announces that it has reached agreement with Christian Le Bras ("CLB") to acquire the 11.03% interest in Venn Life Sciences France S.A...

Grant of Stock Options

RNS Number: 8182Q Venn Life Sciences Holdings PLC 14 September 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company" or the "Group") Grant of Stock Options to Directors and Management Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to...

Venn Life Sciences swings to operating profit

Venn Life Sciences swung to an operating profit of 0.01m, up from a loss of 0.03m in the first half of 2017. FINANCIAL H...

Half-year Report

RNS Number: 4324Q Venn Life Sciences Holdings PLC 12 September 2017 Venn Life Sciences Holdings Plc ("Venn" or the "Company" or the "Group") Half-year Report Interim Results for 6 months ended 30 June 2017 Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and re...

Latest discussion posts More

  • venn priced to fail

    Venn is priced to show annual falls in earnings over several years ie go nowhere or suddenly develop massive losses. That might be right or wrong I really don't know. But with ...
    10-Oct-2017
    conor00
  • Big move up today

    with barely any stock available to buy online. Just moved up another 0.38p on a single #1,400 buy :o)) Could be quite a dramatic rise in store if there's now such a shortage ...
    9-Oct-2017
    gretel
  • Interesting new interview

    with a VENN operations manager re their clinical trial ...
    1-Oct-2017
    gretel

Users' HoldingsMore

Users who hold Venn Life Sciences Holdings also hold..

Codes & Symbols

ISINGB00B9275X97
SymbolsVENN, LSE:VENN, VENN.L, VENN:LN, LON:VENN, XLON:VENN

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account